Mostrar el registro sencillo del ítem

dc.contributor.authorRodriguez-Diaz, Cristina
dc.contributor.authorTaminiau, Bernard
dc.contributor.authorGarcía-García, Alberto
dc.contributor.authorCueto-Sánchez, Alejandro
dc.contributor.authorRobles-Díaz, María Mercedes 
dc.contributor.authorOrtega-Alonso, Aida
dc.contributor.authorMartín-Reyes, Flores
dc.contributor.authorDaube, Georges
dc.contributor.authorSanabria-Cabrera, Judith Adriana 
dc.contributor.authorJiménez-Pérez, Miguel 
dc.contributor.authorLucena-González, María Isabel 
dc.contributor.authorAndrade-Bellido, Raúl Jesús 
dc.contributor.authorGarcía Fuentes, Eduardo
dc.contributor.authorGarcía-Cortés, Miren 
dc.date.accessioned2022-08-24T09:55:53Z
dc.date.available2022-08-24T09:55:53Z
dc.date.issued2022-08
dc.identifier.citationCristina Rodriguez-Diaz, Bernard Taminiau, Alberto García-García, Alejandro Cueto, Mercedes Robles-Díaz, Aida Ortega-Alonso, Flores Martín-Reyes, Georges Daube, Judith Sanabria-Cabrera, Miguel Jimenez-Perez, M. Isabel Lucena, Raúl J. Andrade, Eduardo García-Fuentes, Miren García-Cortes, Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury, Pharmacological Research, Volume 182, 2022, 106348, ISSN 1043-6618, https://doi.org/10.1016/j.phrs.2022.106348es_ES
dc.identifier.urihttps://hdl.handle.net/10630/24812
dc.description.abstractThe gut microbiota could play a significant role in the progression of nonalcoholic fatty liver disease (NAFLD); however, its relevance in drug-induced liver injury (DILI) remains unexplored. Since the two hepatic disorders may share damage pathways, we analysed the metagenomic profile of the gut microbiota in NAFLD, with or without significant liver fibrosis, and in DILI, and we identified the main associated bacterial metabolic pathways. In the NAFLD group, we found a decrease in Alistipes, Barnesiella, Eisenbergiella, Flavonifractor, Fusicatenibacter, Gemminger, Intestinimonas, Oscillibacter, Parasutterella, Saccharoferementans and Subdoligranulum abundances compared with those in both the DILI and control groups. Additionally, we detected an increase in Enterobacter, Klebsiella, Sarcina and Turicibacter abundances in NAFLD, with significant liver fibrosis, compared with those in NAFLD with no/mild liver fibrosis. The DILI group exhibited a lower microbial bacterial richness than the control group, and lower abundances of Acetobacteroides, Blautia, Caloramator, Coprococcus, Flavobacterium, Lachnospira, Natronincola, Oscillospira, Pseudobutyrivibrio, Shuttleworthia, Themicanus and Turicibacter compared with those in the NAFLD and control groups. We found seven bacterial metabolic pathways that were impaired only in DILI, most of which were associated with metabolic biosynthesis. In the NAFLD group, most of the differences in the bacterial metabolic pathways found in relation to those in the DILI and control groups were related to fatty acid and lipid biosynthesis. In conclusion, we identified a distinct bacterial profile with specific bacterial metabolic pathways for each type of liver disorder studied. These differences can provide further insight into the physiopathology and development of NAFLD and DILI.es_ES
dc.description.sponsorshipThis work was supported in part by a grant from the Instituto de Salud Carlos III (Spain) (PI18/01804, PI19/00883, PI21/01248), from the Consejería de Economía, Conocimiento, Empresas y Universidad (Junta de Andalucía, Spain) (PI18–RT‐3364, UMA18-FEDERJA-194), and from the Consejería de Salud (Junta de Andalucía, Spain) (PI-0285–2016). This study has been co-funded by FEDER funds (“A way to make Europe”) (“Andalucía se mueve con Europa”). CRD is supported by a grant from the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de Junta de Andalucía (Spain) (DOC_01610). FMR is supported by a grant from the ISCIII (Spain) (FI19/00189). AC is supported by a grant from the ISCIII (Spain) (IFI18/00047). EGF is supported by the Nicolas Monardes program from the Consejería de Salud de Andalucía (Spain) (C-0031–2016). Funding for open access charge: Universidad de Málaga / CBUA (Spain).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMedicamentos -- Efectoses_ES
dc.subject.otherDrug induced liver injuryes_ES
dc.subject.otherNon-alcoholic fatty liver diseasees_ES
dc.subject.otherLiver fibrosises_ES
dc.subject.otherMetagenomices_ES
dc.subject.otherMetabolic pathwayses_ES
dc.subject.otherGut microbiotaes_ES
dc.titleMicrobiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injuryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doihttps://doi.org/10.1016/j.phrs.2022.106348
dc.rights.ccAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional